No Data
Chinese Biotech Ascentage Pharma's Valuation Driven By Late-Stage De-Risked Assets: JPMorgan
Mirum Pharmaceuticals Says Livmarli Approved in Japan for Pruritus
Express News | Takeda's HyQvia Receives Expanded Market Authorization From Health Canada
Takeda Pharmaceutical To Go Ex-Dividend On March 28th, 2025 With 98 JPY Dividend Per Share
March 27th (Japan Standard Time) - $Takeda Pharmaceutical(4502.JP)$ is trading ex-dividend on March 28th, 2025.Shareholders of record on March 31st, 2025 will receive 98 JPY dividend per share. The
Regarding the application for partial change in manufacturing and marketing approval for the treatment of congenital thrombotic thrombocytopenic purpura "Ajinma intravenous injection 1500" (apadama terase alpha (recombinant) / sinakizada mu terase alpha (
Regarding the partial change in the approval for the manufacture and sale application to expand the indication of "Aginma Injection 1500" (Apadomate Alpha (recombinant) / Sinacasadamate Alpha (recombinant)) for children under 12 years old - March 27, 2025 - Congenital Thrombotic Thrombocytopenic Purpura (cTTP) is an extremely rare blood coagulation disorder characterized by life-threatening acute symptoms and chronic, debilitating symptoms - "Aginma Injection 1500".
Top Gap Ups and Downs on Friday: MUFG, SONY, IBN and More
